Scarica l'app Stockscreener
5.43
1.45%
-0.08
Dopo l'orario di chiusura:
5.57
0.14
+2.58%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$5.51
Aprire:
$5.56
Volume 24 ore:
3.79M
Relative Volume:
2.23
Capitalizzazione di mercato:
$1.11B
Reddito:
-
Utile/perdita netta:
$-129.48M
Rapporto P/E:
-9.7242
EPS:
-0.5584
Flusso di cassa netto:
$-106.97M
1 W Prestazione:
-1.09%
1M Prestazione:
-7.97%
6M Prestazione:
-7.18%
1 anno Prestazione:
+110.47%
Intervallo 1D:
$5.43
$5.68
Intervallo di 1 settimana:
$5.43
$6.025
Portata 52W:
$2.43
$7.005
Savara Inc Stock (SVRA) Company Profile
Nome
Savara Inc
Settore
Industria
Telefono
51285113796
Indirizzo
6836 BEE CAVE ROAD, AUSTIN, TX
Compare SVRA vs VRTX, REGN, ARGX, RVMD, ALNY
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
SVRA
Savara Inc
|
5.43 | 1.13B | 0 | -129.48M | -106.97M | -0.5584 |
VRTX
Vertex Pharmaceuticals Inc
|
479.00 | 121.16B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
667.17 | 68.78B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
888.82 | 57.44B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
188.07 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.40 | 36.28B | 4.29B | 577.22M | 641.34M | 4.2086 |
Savara Inc Stock (SVRA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-04-24 | Ripresa | Oppenheimer | Outperform |
| 2025-10-20 | Iniziato | Wells Fargo | Overweight |
| 2025-08-15 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
| 2025-05-29 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2024-12-20 | Iniziato | Wells Fargo | Overweight |
| 2024-11-13 | Downgrade | Evercore ISI | Outperform → In-line |
| 2024-02-15 | Iniziato | JMP Securities | Mkt Outperform |
| 2023-11-07 | Iniziato | Guggenheim | Buy |
| 2023-05-16 | Aggiornamento | Jefferies | Hold → Buy |
| 2023-03-31 | Downgrade | Jefferies | Buy → Hold |
| 2021-03-16 | Iniziato | Piper Sandler | Overweight |
| 2021-03-15 | Iniziato | Oppenheimer | Outperform |
| 2019-06-13 | Reiterato | H.C. Wainwright | Buy |
| 2019-06-13 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| 2019-06-13 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| 2018-08-13 | Ripresa | ROTH Capital | Neutral |
| 2018-01-03 | Iniziato | Ladenburg Thalmann | Buy |
| 2017-09-27 | Ripresa | ROTH Capital | Buy |
| 2017-09-22 | Iniziato | Jefferies | Buy |
| 2017-09-11 | Iniziato | JMP Securities | Mkt Outperform |
Mostra tutto
Savara Inc Borsa (SVRA) Ultime notizie
Savara Inc (SVRA) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Savara Inc (SVRA) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Savara Inc (SVRA) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Savara Inc (SVRA) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Savara, Inc. Revenue Breakdown – NASDAQ:SVRA - TradingView
TradingKey - TradingKey
SVRA|Savara Inc|Price:5.510|Chg%:-0.240 - TradingKey
Savara Inc. CFO Robert Lutz Secures 70,000 Stock Options and 35,000 RSUs in Insider Transaction - Kalkine Media
Form 4 Savara Inc For: 24 July By Investing.com - Investing.com South Africa
Savara Inc (NASDAQ: SVRA) grants CFO 70,000 options, 35,000 RSUs - Stock Titan
Savara Inc. (SVRA) Edges Lower as Stock Approaches Critical Support at $5.37Demand Zone - dars.gov.et
ETFs Investing in Savara, Inc. Stocks - TradingView
Savara stock gains as Phase 3 data support FDA review of inhaled lung therapy - Ad-hoc-news.de
If You Invested $1,000 in Savara Inc (SVRA) - Stock Titan
Piper Sandler Maintains Savara(SVRA.US) With Buy Rating, Maintains Target Price $16 - Moomoo
Here's Why You Should Add Savara Stock to Your Portfolio Now - Yahoo Finance
What Does the FDA's Priority Review Mean for Savara's MOLBREEVI - Kavout | AI
SVRA Q1 2026 Earnings: EPS Misses Estimates Amid Pre-Revenue StageEarnings Revision Upgrade - dars.gov.et
Join Class Action to Recover Losses from Savara Inc. (SVRA)Contact Levi & Korsinsky Before November 7, 2025 - The National Law Review
Savara Announces Participation in the 2026 Jefferies Global Healthcare Conference - AOL.com
Savara Presented New Biomarker Data from the IMPALA-2 Phase 3 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the American Thoracic Society (ATS) International Conference 20 - AOL.com
Savara stock. Thin-source profile holds the focus. - ad-hoc-news.de
SVRA Q1 2026 Earnings: EPS Misses Estimates as Pre-Commercial Spending RampsOne-Time Gain Impact - dars.gov.et
Enterprise value to EBIT forward of Savara, Inc. – NASDAQ:SVRA - TradingView
Enterprise value to EBITDA forward of Savara, Inc. – NASDAQ:SVRA - TradingView
Price to earnings forward of Savara, Inc. – NASDAQ:SVRA - TradingView
Savara Inc focuses on respiratory drug development as investors watch clinical progress - Ad-hoc-news.de
Price to sales forward of Savara, Inc. – NASDAQ:SVRA - TradingView
Enterprise value to revenue forward of Savara, Inc. – NASDAQ:SVRA - TradingView
Savara Inc. (SVRA) Class Action Lawsuit: Levi & Korsinsky Reminds Investors of November 7, 2025 Deadline - The National Law Review
SVRA Q1 2026 Earnings: EPS Misses Estimates as Clinical Development AdvancesGrowth Acceleration Report - dars.gov.et
Securities Lawsuit Alert: Savara Inc. (SVRA) InvestorsContact Levi & Korsinsky Before November 7, 2025 - The National Law Review
Class Action Lawsuit Alert: Levi & Korsinsky Reminds Savara Inc. (SVRA) Investors of November 7, 2025 Deadline - The National Law Review
SVRA SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Anno - The National Law Review
Levi & Korsinsky Notifies Savara Inc. (SVRA) InvestorsLead Plaintiff Deadline on November 7, 2025 - The National Law Review
Investors SueWallSt as Savara Inc. Faces Securities Fraud Allegations - The National Law Review
Investors in Savara Inc. (SVRA): Protect Your RightsContact Levi & Korsinsky Before November 7, 2025 - The National Law Review
What Savara Investors Should Know About This 580,187-Option Exercise and FDA Timeline - AOL.com
Savara, Inc. Actuals & Estimates (FWB:YB4P) - TradingView
SVRA Forecast — Price Target — Prediction for 2027 - TradingView
Savara, Inc. Actuals & Estimates (SWB:YB4P) - TradingView
YB4P Forecast — Price Target — Prediction for 2027 - TradingView
Savara CFO David Lowrance sells $2.24m in company stock By Investing.com - Investing.com Nigeria
Savara CFO David Lowrance sells $2.24m in company stock - Investing.com UK
Form 4 Savara Inc For: 22 June By Investing.com - Investing.com Nigeria
Savara (SVRA) CFO exercises 580K options and sells 394K shares in Form 4 - Stock Titan
Form 144 Savara Inc For: 22 June By Investing.com - Investing.com South Africa
Form 144 Savara Inc For: 22 June - Investing.com India
[144] Savara Inc SEC Filing - Stock Titan
Savara Inc Azioni (SVRA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.97%
0.83%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):